Patent · US Active

Rapidly-orodispersible tablets having an in interior cavity

US11433022B2 · kind B2 · utility

0Cited by
45References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 28, 2021
Grant dateSep 6, 2022
Priority date
Expiry dateOct 28, 2041

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K9/2095
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A rapidly-orodispersible dosage form comprising a porous, bound-powder matrix and one or more internal cavities is provided, as well as three-dimensional printing methods for making the same. Each internal cavity is configured to contain one or more payloads, particularly pharmaceutical medicaments, while isolating the payloads from the external environment outside of the dosage form. Each payload can be contained within its cavity in its native form without having to be combined with the bound-powder matrix or binding liquid. Dosage forms can disintegrate in water or saliva in less than two minutes, independently of the payload(s) or medicament(s) contained within. The dosage forms can be formed as unitary tablets, or as two-piece tablets comprising a container body and a lidding body that are secured together to isolate the one or more cavities and their payloads inside.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.